PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29744867-0 2018 P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib. lorlatinib 145-155 anaplastic lymphoma kinase Mus musculus 126-129 30662002-4 2019 METHODS: We established lorlatinib-resistant cells harboring ALK-I1171N or -G1202R compound mutations by performing ENU mutagenesis screening or using an in vivo mouse model. lorlatinib 24-34 anaplastic lymphoma kinase Mus musculus 61-64 30660696-0 2019 Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib. lorlatinib 131-141 anaplastic lymphoma kinase Mus musculus 112-115 30660696-1 2019 Lorlatinib, a novel generation oral anaplastic lymphoma kinase (ALK) and ROS1 inhibitor with high membrane and blood-brain barrier permeability, recently received accelerated approval for treatment of ALK-rearranged non-small-cell lung cancer (NSCLC), and its further clinical development is ongoing. lorlatinib 0-10 anaplastic lymphoma kinase Mus musculus 36-62 30660696-1 2019 Lorlatinib, a novel generation oral anaplastic lymphoma kinase (ALK) and ROS1 inhibitor with high membrane and blood-brain barrier permeability, recently received accelerated approval for treatment of ALK-rearranged non-small-cell lung cancer (NSCLC), and its further clinical development is ongoing. lorlatinib 0-10 anaplastic lymphoma kinase Mus musculus 64-67 30660696-1 2019 Lorlatinib, a novel generation oral anaplastic lymphoma kinase (ALK) and ROS1 inhibitor with high membrane and blood-brain barrier permeability, recently received accelerated approval for treatment of ALK-rearranged non-small-cell lung cancer (NSCLC), and its further clinical development is ongoing. lorlatinib 0-10 anaplastic lymphoma kinase Mus musculus 201-204 30322862-3 2018 Lorlatinib is a third-generation ALK inhibitor that inhibits most ALK mutants resistant to current ALK inhibitors. lorlatinib 0-10 anaplastic lymphoma kinase Mus musculus 33-36 30322862-3 2018 Lorlatinib is a third-generation ALK inhibitor that inhibits most ALK mutants resistant to current ALK inhibitors. lorlatinib 0-10 anaplastic lymphoma kinase Mus musculus 66-69 30322862-3 2018 Lorlatinib is a third-generation ALK inhibitor that inhibits most ALK mutants resistant to current ALK inhibitors. lorlatinib 0-10 anaplastic lymphoma kinase Mus musculus 66-69 30322862-12 2018 These data provide an extensive characterization of resistance mechanisms that may arise in different ALK-positive cancers following lorlatinib treatment. lorlatinib 133-143 anaplastic lymphoma kinase Mus musculus 102-105 30322862-13 2018 SIGNIFICANCE: High-throughput genomic, transcriptomic, and proteomic profiling reveals various mechanisms by which multiple tumor types acquire resistance to the third-generation ALK inhibitor lorlatinib. lorlatinib 193-203 anaplastic lymphoma kinase Mus musculus 179-182 30149189-0 2018 Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates. lorlatinib 139-149 anaplastic lymphoma kinase Mus musculus 98-101 29744867-1 2018 Lorlatinib (PF-06463922) is a promising oral anaplastic lymphoma kinase (ALK) and ROS1 inhibitor currently in Phase III clinical trials for treatment of non-small-cell lung cancer (NSCLC) containing an ALK rearrangement. lorlatinib 0-10 anaplastic lymphoma kinase Mus musculus 45-71 29744867-1 2018 Lorlatinib (PF-06463922) is a promising oral anaplastic lymphoma kinase (ALK) and ROS1 inhibitor currently in Phase III clinical trials for treatment of non-small-cell lung cancer (NSCLC) containing an ALK rearrangement. lorlatinib 0-10 anaplastic lymphoma kinase Mus musculus 73-76 29744867-1 2018 Lorlatinib (PF-06463922) is a promising oral anaplastic lymphoma kinase (ALK) and ROS1 inhibitor currently in Phase III clinical trials for treatment of non-small-cell lung cancer (NSCLC) containing an ALK rearrangement. lorlatinib 0-10 anaplastic lymphoma kinase Mus musculus 202-205 29744867-1 2018 Lorlatinib (PF-06463922) is a promising oral anaplastic lymphoma kinase (ALK) and ROS1 inhibitor currently in Phase III clinical trials for treatment of non-small-cell lung cancer (NSCLC) containing an ALK rearrangement. lorlatinib 12-23 anaplastic lymphoma kinase Mus musculus 45-71 29744867-1 2018 Lorlatinib (PF-06463922) is a promising oral anaplastic lymphoma kinase (ALK) and ROS1 inhibitor currently in Phase III clinical trials for treatment of non-small-cell lung cancer (NSCLC) containing an ALK rearrangement. lorlatinib 12-23 anaplastic lymphoma kinase Mus musculus 73-76 29744867-1 2018 Lorlatinib (PF-06463922) is a promising oral anaplastic lymphoma kinase (ALK) and ROS1 inhibitor currently in Phase III clinical trials for treatment of non-small-cell lung cancer (NSCLC) containing an ALK rearrangement. lorlatinib 12-23 anaplastic lymphoma kinase Mus musculus 202-205 29550682-0 2018 Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry. lorlatinib 64-74 anaplastic lymphoma kinase Mus musculus 50-53 29650534-3 2018 To define the spectrum of ALK mutations that confer lorlatinib resistance, we performed accelerated mutagenesis screening of Ba/F3 cells expressing EML4-ALK. lorlatinib 52-62 anaplastic lymphoma kinase Mus musculus 26-29 29550682-1 2018 A bio-analytical assay for the first third generation ALK inhibitor lorlatinib in mouse plasma was developed and validated. lorlatinib 68-78 anaplastic lymphoma kinase Mus musculus 54-57 29048652-7 2017 Finally, we showed that the combined use of ALK and Src inhibitors inhibited the growth of other ALK-NSCLC cell lines, including those that were ceritinib or lorlatinib resistant. lorlatinib 158-168 anaplastic lymphoma kinase Mus musculus 44-47 29048652-7 2017 Finally, we showed that the combined use of ALK and Src inhibitors inhibited the growth of other ALK-NSCLC cell lines, including those that were ceritinib or lorlatinib resistant. lorlatinib 158-168 anaplastic lymphoma kinase Mus musculus 97-100 31943796-11 2020 KEY POINTS: ALK compound mutation was found in a clinical sample that was resistant to lorlatinib after sequential ALK-tyrosine kinase inhibitor (TKI) treatment. lorlatinib 87-97 anaplastic lymphoma kinase Mus musculus 115-118 34819663-7 2021 Treatment of Ba/F3 cells expressing CLIP1-LTK with lorlatinib, an ALK inhibitor, inhibited CLIP1-LTK kinase activity, suppressed proliferation and induced apoptosis. lorlatinib 51-61 anaplastic lymphoma kinase Mus musculus 66-69